In:
Cancer, Wiley, Vol. 123, No. 2 ( 2017-01-15), p. 303-311
Kurzfassung:
A randomized, placebo‐controlled, phase 2 trial is used to evaluate the combination of vandetanib with platinum and etoposide for patients with previously untreated extensive‐stage small cell lung cancer (planned maximum of 6 cycles with no maintenance therapy). With 74 patients enrolled and 33 ultimately randomized to each arm, no significant difference is demonstrated in the time to progression or median overall survival; however, there is an increase in nonhematologic toxicity with vandetanib versus a placebo.
Materialart:
Online-Ressource
ISSN:
0008-543X
,
1097-0142
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2017
ZDB Id:
1479932-7
ZDB Id:
2599218-1
ZDB Id:
2594979-2
ZDB Id:
1429-1
